RT Journal Article
T1 Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients.
A1 Montes, Paola
A1 Guerra-Librero, Ana
A1 Garcia, Paloma
A1 Cornejo-Calvo, María Elena
A1 Lopez, Maria del Señor
A1 Haro, Tomas de
A1 Martinez-Ruiz, Laura
A1 Escames, Germaine
A1 Acuña-Castroviejo, Dario
K1 5-azacitidine
K1 cytokines
K1 inflammation
K1 myelodysplastic syndrome (MDS)
K1 oxidative stress
K1 somatic alterations
AB This study focused on the impact of the treatment with the hypomethylating agent 5-azacitidine on the redox status and inflammation in 24 MDS patients. Clinical and genetic features of MDS patients were recorded, and peripheral blood samples were used to determine the activity of the endogenous antioxidant defense system (superoxide dismutase, SOD; catalase, CAT; glutathion peroxidase, GPx; and reductase, GRd, activities), markers of oxidative damage (lipid peroxidation, LPO, and advanced oxidation protein products, AOPP). Moreover, pro-inflammatory cytokines and plasma nitrite plus nitrate levels as markers of inflammation, as well as CoQ10 plasma levels, were also measured. Globally, MDS patients showed less redox status in terms of a reduction in the GSSG/GSH ratio and in the LPO levels, as well as increased CAT activity compared with healthy subjects, with no changes in SOD, GPx, and GRd activities, or AOPP levels. When analyzing the evolution from early to advanced stages of the disease, we found that the GPx activity, GSSG/GSH ratio, LPO, and AOPP increased, with a reduction in CAT. GPx changes were related to the presence of risk factors such as high-risk IPSS-R or mutational score. Moreover, there was an increase in IL-2, IL-6, IL-8, and TNF-α plasma levels, with a further increase of IL-2 and IL-10 from early to advanced stages of the disease. However, we did not observe any association between inflammation and oxidative stress. Finally, 5-azacitidine treatment generated oxidative stress in MDS patients, without affecting inflammation levels, suggesting that oxidative status and inflammation are two independent processes.
SN 2076-3921
YR 2022
FD 2022-01-06
LK http://hdl.handle.net/10668/20770
UL http://hdl.handle.net/10668/20770
LA en
NO Montes P, Guerra-Librero A, García P, Cornejo-Calvo ME, López MDS, Haro T, et al. Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients. Antioxidants (Basel). 2022 Jan 9;11(1):139
NO This study was partially supported by grants from the Instituto de Salud Carlos III throughthe project CB/10/00238 (co-funded by European Regional Development Fund/European SocialFund “Investing in your future”); the Consejería de Economía, Innovación, Ciencia y Empleo, Juntade Andalucía (CTS-101), Spain; and the UGC de Laboratorios Clínicos, Hospital Universitario SanCecilio, Granada, Spain
DS RISalud
RD Apr 5, 2025